Figure 3.

In vivo targeting behaviors of biological targeting magnetic NPs. (A) Homogenates of tumor tissues and normal organs were cultured on solid BL agar. (B) In vivo targeting efficiency before and after PFH@CL/Fe₃O₄ NPs with intravenous administration. Fluorescence intensity of tumor-bearing mice at pre-injection and 6h, 24h, 30h, 48h post-injection of targeted group and non-targeted group. (C) The corresponding in vivo quantitative fluorescence intensity of tumor. The fluorescence intensity in targeted group was slightly higher than that in non-targeted group 6h after injection of NPs (**p < 0.01). The fluorescence intensity in targeted group was significantly higher than that in non-targeted group 30h after injection of NPs (***p < 0.001). (D) In vitro fluorescence intensity of the major organs (heart, liver, spleen, lung and kidney) and tumors 48h after injection of targeted group and non-targeted group. (E) The corresponding in vitro quantitative fluorescence intensity of major organs and tumors. The fluorescence intensity of tumor in targeted group was significantly higher than that in non-targeted group (***p < 0.001).

Abbreviations: Fe₃O₄, Superparamagnetic Iron Oxide; PFH, perfluorohexanes; CL, cationic liposome; NPs, nanoparticles; B.Bifidum, Bifidobacterium bifidum strain ATCC 29521; FITC, fluorescein isothiocyanate.